Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8 + PD ‐1 − tumor‐infiltrating T cells in PD‐L1 ‐enriched tumor microenvironment-Reference-Cited by-同舟云学术

Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8 + PD ‐1 − tumor‐infiltrating T cells in PD‐L1 ‐enriched tumor microenvironment

Published:2021-03-23 Issue:1 Volume:149 Page:214-227
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Eissa Ibrahim Ragab¹²³,Mukoyama Nobuaki⁴,Abdelmoneim Mohamed¹²,Naoe Yoshinori¹,Matsumura Shigeru¹,Bustos‐Villalobos Itzel¹,Ichinose Toru¹,Miyajima Noriyuki⁵,Morimoto Daishi²,Tanaka Maki⁶,Fujimoto Yasushi⁷,Sone Michihiko⁴,Kodera Yasuhiro²,Kasuya Hideki¹

Affiliation:

1. Cancer Immune Therapy Research Center, Graduate School of Medicine Nagoya University Nagoya Japan

2. Department of Surgery II, Graduate School of Medicine Nagoya University Nagoya Japan

3. Faculty of Science Tanta University Tanta Egypt

4. Department of Otolaryngology, Graduate School of Medicine Nagoya University Nagoya Japan

5. Department of Transplantation and Endocrine Surgery, Graduate School of Medicine Nagoya University Nagoya Japan

6. Department of Clinical Development & Strategy Takara Bio Inc. Kusatsu Japan

7. Department of Otolaryngology Aichi Medical University Nagakute Japan

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33550

Reference53 articles.

1. Oncolytic viruses as engineering platforms for combination immunotherapy

2. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

3. CTLA-4 and PD-1 Pathways

4. T Cell Dysfunction and Exhaustion in Cancer

5. PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06);Journal for ImmunoTherapy of Cancer;2024-03

2. STING activator 2′3′‐cGAMP enhanced HSV‐1‐based oncolytic viral therapy;Molecular Oncology;2024-02-23

3. Development and application of oncolytic viruses as the nemesis of tumor cells;Frontiers in Microbiology;2023-06-12

4. Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model;Scientific Reports;2022-12-13

5. Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma;Cancer Science;2022-11-22